-
Makers Of Insulin Brands Decides To Appeal Against NPPA – (LLY, NVO, PFE, MRK, BMY)
After the National Pharmaceutical Pricing Authority in India has discarded the requests of Eli Lilly & Co. (NYSE:LLY) and two others to raise prices of their insulin brands, they are ready to appeal against the drug price regulator’s decision to further reduce their net margins on the diabetes medicine in public interest, alleging discriminatory treatment.…
-
NPPA Maintains Current Prices Of Insulin Formulations – (LLY, GSK, PFE, MRK, JNJ)
The request from key pharma companies such as Eli Lilly & Co. (NYSE:LLY) and Biocon to raise the price of insulin used for diabetes treatment has been turned down by National Pharmaceutical Pricing Authority (NPPA), the national body set up by the Indian government to control prices of medicines. The drug price regulator said while…